tuneTypical Dose
1.6-3
Fiber Supplement
Chitosan
Chitosan (deacetylated chitin)
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
4-13+ weeks. Stronger biomarker signals often emerge by ~12 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Chitosan is a shellfish-derived fiber-like polymer marketed for weight loss and cholesterol support, but its real-world effects are modest.
Controlled human evidence still argues against the old fat-blocker marketing. A newer obesity-indicator meta-analysis found only small reductions in body weight and body-fat percentage, with no clear BMI or waist benefit. That keeps chitosan in the low-impact adjunct category, where expectations should stay narrow and objective follow-up matters.
Gut lipid/interference hypothesis with high inter-study variation. Practical clinical effect is usually modest.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Modest body-weight or anthropometric improvement in some overweight adults
- Small reduction in total cholesterol in pooled RCT settings
Secondary Outcomes
- Possible fasting glucose/HbA1c improvement at ≥13 weeks in metabolic-risk populations
- Fat absorption effects are inconsistent and often clinically small
Safety
Contraindications and Interactions
Contraindications
- Severe shellfish allergy to product source
- Active bowel obstruction/malabsorption
- Unstable GI disease with high constipation burden
Side effects
- Mild GI symptoms
- Constipation/altered stool pattern
- Rare fatigue or headache
Interactions
- Potential absorption interaction with lipophilic drugs
- Concurrent fat-binding supplements may overlap
- Fat-soluble micronutrient timing interactions
Avoid if
- Pregnancy and breastfeeding unless clinically supervised
- Recent major GI surgery
- Concurrent multiple bowel-altering agents
Evidence
Study-level References
chitosan-SRC-001Phase IV, multicentre, single-blind randomized placebo-controlled trial
Sourceopen_in_newSengupta K et al. *Nutrients* 2016. PMID: 26747458
Population: Overweight/obese adults (96 participants; 64 chitosan, 32 placebo)
Dose protocol: 500 mg chitosan (5/day) for 90 days
Key findings: Reported mean weight reductions at day 45 (-1.78 ±1.37 kg) and day 90 (-3.10 ±1.95 kg).
Notes: Industry-adjacent design and regional cohort context.
Paper content
Reported mean weight reductions at day 45 (-1.78 ±1.37 kg) and day 90 (-3.10 ±1.95 kg).
chitosan-SRC-002Randomized, placebo-controlled, double-blind trial
Sourceopen_in_newPittler M H et al. *Eur J Clin Nutr* 1999. PMID: 10369493
Population: Overweight adults (34 participants)
Dose protocol: Four capsules twice daily for 28 days
Key findings: No significant changes in body weight, BMI, lipids, or fat-soluble vitamins.
Notes: Small sample and short follow-up period.
Paper content
No significant changes in body weight, BMI, lipids, or fat-soluble vitamins.
chitosan-SRC-003Randomized, double-blind, placebo-controlled trial
Sourceopen_in_newBokura H et al. *Eur J Clin Nutr* 2003. PMID: 12771974
Population: Women with mild to moderate hypercholesterolemia (84 analyzed; 41 chitosan)
Dose protocol: 1.2 g/day for 28 and 56 days
Key findings: Total cholesterol reduced versus placebo. Stronger in older subgroup, with mild safety profile.
Notes: Small, older trial. Age-subgroup effect not powered for broad generalization.
Paper content
Total cholesterol reduced versus placebo; stronger in older subgroup, with mild safety profile.
chitosan-SRC-004Meta-analysis with trial sequential analysis
Sourceopen_in_newSengupta K et al. *Nutr J* 2020. PMID: 33261597
Population: 10 RCTs, n=1473 participants with metabolic syndrome-related disorders
Dose protocol: Chitosan 1.6-3 g/day and duration stratification
Key findings: Fasting glucose and HbA1c reduced on pooled analysis. Insulin effect not significant.
Notes: Endpoint reporting and blinding variability in pooled studies.
Paper content
Fasting glucose and HbA1c reduced on pooled analysis; insulin effect not significant.
chitosan-SRC-005Single-blind, placebo-controlled physiological fat-absorption trial
Sourceopen_in_newGades MD et al. *J Am Diet Assoc* 2005. PMID: 15635349
Population: Men and women (24 participants)
Dose protocol: 2.5 g/day (2 capsules, 5 times/day) in 12-day repeated-meal framework
Key findings: Fecal fat increase was minor and clinically insignificant.
Notes: Physiologic endpoint-focused. Not powered for long-term weight endpoints.
Paper content
Fecal fat increase was minor and clinically insignificant.
chitosan-SRC-006Meta-analysis of randomized placebo-controlled trials
Sourceopen_in_newBaker W L et al. *Ann Nutr Metab* 2009. PMID: 19923803
Population: Hypercholesterolemic adults; 6 studies, n=416
Dose protocol: Formulation-specific pooled RCT doses
Key findings: Significant total cholesterol reduction (~-11.59 mg/dL). No clear LDL/HDL/TG effect.
Notes: Moderate heterogeneity by product and follow-up design.
Paper content
Significant total cholesterol reduction (~-11.59 mg/dL); no clear LDL/HDL/TG effect.
chitosan-SRC-007Systematic review and meta-analysis
Sourceopen_in_newA Systematic Review and Meta-Analysis to Evaluate the Effects of Chitosan on Obesity Indicators. Food Sci Nutr. 2024. doi:10.1002/fsn3.4596. PMID:39723066.
Population: Adults enrolled in randomized chitosan supplementation trials.
Dose protocol: Chitosan supplementation across 19 adult randomized trials
Key findings: Meta-analysis found small reductions in body weight and body-fat percentage with no clear effect on BMI or waist circumference.
Notes: This is the best modern anchor for keeping any weight-loss claim narrow and low confidence.
Paper content
Chitosan produced small pooled improvements in body weight and body-fat percentage but not in BMI or waist circumference. This is the best modern corrective source for narrowing chitosan to a low-impact adjunct and rejecting classic fat-blocker marketing.